Variable | Placebo | ASA | Clopidogrel | p-value | ||
ASA versus placebo | Clopidogrel versus placebo | ASA versus clopidogrel | ||||
Serum TxB2 ng·mL−1 | 63±9 | 13±9 | 59±9 | <0.0001 | 0.75 | 0.0003 |
Urine Tx-M ng·mg Cr−1 | 0.33±1.1 | 0.09±1.1 | 0.32±1.1 | <0.0001 | 0.44 | <0.0001 |
Urine PGI-M ng·mg Cr−1 | 2.6±0.6 | 2.4±0.5 | 3.2±0.6 | 0.68 | 0.45 | 0.24 |
Urine Tx-M/PGI-M | 0.46±1.2 | 0.16±1.2 | 0.42±1.2 | <0.0001 | 0.68 | <0.0001 |
Plasma P-selectin ng·mL−1 | 35±2 | 31±2 | 31±2 | 0.05 | 0.09 | 0.85 |
Data are presented as least squares mean±se after adjustment for period, sequence, centre, epoprostenol use and the drug by epoprostenol interaction. ASA: aspirin; TxB2: thromboxane B2; Tx-M: 11-dehydro-thromboxane B2; Cr: creatinine; PGI-M: 2,3-dinor-6-keto-prostaglandin F1α.